IQ-AI sponsors Phase I GBM treatment trial

IQ-AI finances Phase I trial evaluating Gallium Maltolate in treatment of Glioblastoma Multiforme

Imaging Biometrics’ IB Clinic software used to assess performance

IQ-AI Limited (LON:IQAI) — IQ-AI commits to funding a phase I clinical trial to evaluate the safety and efficacy of Gallium Maltolate (GaM) in the treatment of Glioblastoma Multiforme (GBM). Its Imaging Biometrics (IB) subsidiary is providing IB Clinic brain tumour assessment software to help measure tumour progression.

IB is partnering with a team led by oncologist Christopher Chitambar, MD, of the Medical College of Wisconsin, and including Lawrence Bernstein, PhD, the developer of GaM, in performing this trial.

Read full release here.